相似文献
1
Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine.
Inflamm Bowel Dis. 2015 Oct;21(10):2467-74. doi: 10.1097/MIB.0000000000000444.
2
New proteomic approaches for biomarker discovery in inflammatory bowel disease.
Inflamm Bowel Dis. 2010 Jul;16(7):1239-46. doi: 10.1002/ibd.21212.
3
Personalized medicine in the treatment of inflammatory bowel diseases.
Ter Arkh. 2018 Feb 15;90(2):4-11. doi: 10.26442/terarkh20189024-11.
4
Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy.
Aliment Pharmacol Ther. 2018 Dec;48(11-12):1213-1231. doi: 10.1111/apt.15033. Epub 2018 Oct 30.
5
Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine.
Expert Rev Clin Immunol. 2021 Aug;17(8):871-881. doi: 10.1080/1744666X.2021.1945442. Epub 2021 Jun 28.
6
Biomarkers in inflammatory bowel disease: current practices and recent advances.
Transl Res. 2012 Apr;159(4):313-25. doi: 10.1016/j.trsl.2012.01.001. Epub 2012 Feb 1.
7
Omics Approaches to Identify Potential Biomarkers of Inflammatory Diseases in the Focal Adhesion Complex.
Genomics Proteomics Bioinformatics. 2017 Apr;15(2):101-109. doi: 10.1016/j.gpb.2016.12.003. Epub 2017 Apr 1.
8
Clinical Utility of Biomarkers in IBD.
Curr Gastroenterol Rep. 2015 Jul;17(7):26. doi: 10.1007/s11894-015-0449-x.
9
Challenges in IBD Research: Precision Medicine.
Inflamm Bowel Dis. 2019 May 16;25(Suppl 2):S31-S39. doi: 10.1093/ibd/izz078.
10
Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification.
Int J Mol Sci. 2018 Sep 15;19(9):2775. doi: 10.3390/ijms19092775.
引用本文的文献
1
Intestinal Biomarkers and Their Importance in Canine Enteropathies.
Vet Med Int. 2024 Nov 13;2024:7409482. doi: 10.1155/vmi/7409482. eCollection 2024.
2
Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
Adv Ther. 2023 Oct;40(10):4440-4459. doi: 10.1007/s12325-023-02603-0. Epub 2023 Jul 31.
3
Serum proteome profiles in cats with chronic enteropathies.
J Vet Intern Med. 2023 Jul-Aug;37(4):1358-1367. doi: 10.1111/jvim.16743. Epub 2023 Jun 6.
4
The Current Status of Molecular Biomarkers for Inflammatory Bowel Disease.
Biomedicines. 2022 Jun 24;10(7):1492. doi: 10.3390/biomedicines10071492.
5
Proteomic Analysis of Potential Targets for Non-Response to Infliximab in Patients With Ulcerative Colitis.
Front Pharmacol. 2022 Jun 13;13:905133. doi: 10.3389/fphar.2022.905133. eCollection 2022.
6
Crohn's disease-related single nucleotide polymorphisms are associated with ileal pouch afferent limb stenosis.
J Gastrointest Surg. 2021 Sep;25(9):2377-2386. doi: 10.1007/s11605-020-04884-0. Epub 2021 Jan 14.
7
Proteomic insights on the metabolism in inflammatory bowel disease.
World J Gastroenterol. 2020 Feb 21;26(7):696-705. doi: 10.3748/wjg.v26.i7.696.
8
Precision medicine in inflammatory bowel disease: concept, progress and challenges.
F1000Res. 2020 Jan 28;9. doi: 10.12688/f1000research.20928.1. eCollection 2020.
9
Candida utilis yeast as a functional protein source for Atlantic salmon (Salmo salar L.): Local intestinal tissue and plasma proteome responses.
PLoS One. 2019 Dec 30;14(12):e0218360. doi: 10.1371/journal.pone.0218360. eCollection 2019.
10
Biomarker discovery in inflammatory bowel diseases using network-based feature selection.
PLoS One. 2019 Nov 22;14(11):e0225382. doi: 10.1371/journal.pone.0225382. eCollection 2019.
本文引用的文献
1
Aberrant expression of microRNAs in serum may identify individuals with pancreatic cancer.
Int J Clin Exp Med. 2014 Dec 15;7(12):5226-34. eCollection 2014.
2
Identification of a metastasis-specific MicroRNA signature in human colorectal cancer.
J Natl Cancer Inst. 2015 Feb 6;107(3). doi: 10.1093/jnci/dju492. Print 2015 Mar.
3
Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
Inflamm Bowel Dis. 2015 Feb;21(2):331-6. doi: 10.1097/MIB.0000000000000273.
4
Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature.
Mol Oncol. 2015 Mar;9(3):704-14. doi: 10.1016/j.molonc.2014.11.004. Epub 2014 Nov 28.
5
Longitudinal study of circulating protein biomarkers in inflammatory bowel disease.
J Proteomics. 2015 Jan 1;112:166-79. doi: 10.1016/j.jprot.2014.09.002. Epub 2014 Sep 16.
6
Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib.
Br J Cancer. 2014 Oct 14;111(8):1590-604. doi: 10.1038/bjc.2014.436. Epub 2014 Aug 14.
7
Validation of a blood protein signature for non-small cell lung cancer.
Clin Proteomics. 2014 Aug 1;11(1):32. doi: 10.1186/1559-0275-11-32. eCollection 2014.
8
Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer.
Int J Cancer. 2015 Feb 15;136(4):854-62. doi: 10.1002/ijc.29041. Epub 2014 Jul 1.
9
MicroRNA profiles discriminate among colon cancer metastasis.
PLoS One. 2014 Jun 12;9(6):e96670. doi: 10.1371/journal.pone.0096670. eCollection 2014.
10
C-reactive protein and lung diseases.
Int J Biochem Cell Biol. 2014 Aug;53:77-88. doi: 10.1016/j.biocel.2014.05.016. Epub 2014 May 19.
Zotero 插件